PL2033635T3 - Zastosowanie kwasu fenylomasłowego lub jego soli do leczenia świądu - Google Patents

Zastosowanie kwasu fenylomasłowego lub jego soli do leczenia świądu

Info

Publication number
PL2033635T3
PL2033635T3 PL07115426T PL07115426T PL2033635T3 PL 2033635 T3 PL2033635 T3 PL 2033635T3 PL 07115426 T PL07115426 T PL 07115426T PL 07115426 T PL07115426 T PL 07115426T PL 2033635 T3 PL2033635 T3 PL 2033635T3
Authority
PL
Poland
Prior art keywords
pruritus
salt
phenylbutyric acid
treat pruritus
mucosa
Prior art date
Application number
PL07115426T
Other languages
English (en)
Inventor
Yih-Lin Chung
Nam-Mew Pui
Wei-Wei- Chang
Original Assignee
Sunny Pharmtech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunny Pharmtech Inc filed Critical Sunny Pharmtech Inc
Publication of PL2033635T3 publication Critical patent/PL2033635T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07115426T 2007-08-31 2007-08-31 Zastosowanie kwasu fenylomasłowego lub jego soli do leczenia świądu PL2033635T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07115426A EP2033635B1 (en) 2007-08-31 2007-08-31 Use of phenylbutyric acid or salts thereof for treating pruritus

Publications (1)

Publication Number Publication Date
PL2033635T3 true PL2033635T3 (pl) 2012-01-31

Family

ID=38969500

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07115426T PL2033635T3 (pl) 2007-08-31 2007-08-31 Zastosowanie kwasu fenylomasłowego lub jego soli do leczenia świądu

Country Status (5)

Country Link
EP (2) EP2033635B1 (pl)
AT (1) ATE522208T1 (pl)
ES (1) ES2371671T3 (pl)
PL (1) PL2033635T3 (pl)
PT (1) PT2033635E (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087474A2 (en) 2008-01-08 2009-07-16 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
WO2012131069A1 (en) * 2011-03-31 2012-10-04 Proponent Biotech Gmbh Short chain fatty acids and their derivatives for use in treatment immunogenic disorders
ES2748632T3 (es) 2012-10-03 2020-03-17 Proponent Biotech Gmbh Composición farmacéutica que comprende ácido propiónico para uso en el tratamiento de infecciones víricas
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
CN109589306A (zh) * 2017-09-30 2019-04-09 上海交通大学医学院附属第九人民医院 脂质体在制备用于清除蛋白结合毒素的药物制剂中的用途
KR102059027B1 (ko) * 2018-01-12 2019-12-24 주식회사 비엔에이치리서치 Hdac6 억제제를 유효성분으로 포함하는 가려움증 예방 또는 치료용 약제학적 조성물
DE102018123014A1 (de) * 2018-09-19 2020-03-19 Flexopharm Brain Gmbh & Co. Kg Mittel zur Verwendung bei der Behandlung von Patienten mit systemischen Entzündungserscheinungen und oxidativem Stress bei terminaler Niereninsuffizienz
CN109758444B (zh) * 2019-03-27 2021-08-24 中国农业科学院特产研究所 2-甲基取代脂肪酸在抗氧化方面的应用
WO2024117172A1 (ja) * 2022-11-30 2024-06-06 花王株式会社 痒みの予防又は改善剤
CN120379658A (zh) * 2022-11-30 2025-07-25 花王株式会社 发痒的预防或改善剂
US20250352498A1 (en) * 2024-04-12 2025-11-20 Aardvark Therapeutics Inc. Pharmaceutical formulations containing phenylbutyrate and methods thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207241A (en) * 1967-01-13 1980-06-10 Syntex Corporation 2-Naphthyl acetic acid derivatives and compositions and methods thereof
EP1656935A1 (en) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Use of physiologically active fatty acids for the treatment of pruritus
GB0617191D0 (en) * 2006-08-31 2006-10-11 York Pharma Plc Improvements in pharmaceutical compositions

Also Published As

Publication number Publication date
ATE522208T1 (de) 2011-09-15
EP2033635A1 (en) 2009-03-11
EP2033635B1 (en) 2011-08-31
EP2030616A1 (en) 2009-03-04
ES2371671T3 (es) 2012-01-09
PT2033635E (pt) 2011-12-15

Similar Documents

Publication Publication Date Title
PL2033635T3 (pl) Zastosowanie kwasu fenylomasłowego lub jego soli do leczenia świądu
WO2009062118A3 (en) Modulation of protein trafficking
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
HK1201065A1 (en) Novel quinoxaline inhibitors of pi3k
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
CO6290687A2 (es) Inhibidores de cinasa pim y metodos para su uso
MX394764B (es) Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
WO2012050831A3 (en) Combination treatment for dermatological conditions
WO2012002687A3 (en) Methods for treating bipolar disorder
BR112015019369A2 (pt) derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra)
WO2012135812A3 (en) Treatment for dermatological pathologies
BR112013007343A2 (pt) métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica
AR086444A1 (es) Composiciones farmaceuticas y metodos para tratar el cancer
BR112014010729A2 (pt) métodos para tratamento de ataques de gota
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
BRPI0703970A2 (pt) tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona
UA112418C2 (uk) Терапевтичний болезаспокійливий засіб
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
BR112015019307A2 (pt) derivados de ácido butanoico substituído com bisfenila como inibidores de nep com eficácia in vivo melhorada
BR112014030288A2 (pt) composição farmacêutica
BR112015014836A2 (pt) método para tratamento alvo de uma ou mais condições do fígado, e, uso oral de uma quantidade terapeuticamente eficaz de pelo menos um análogo de diamidina ou um sal farmaceuticamente aceitável da mesma